€27.50
0.18% day before yesterday
Xetra, Sep 19, 05:36 pm CET
ISIN
DE000BAY0017
Symbol
BAYN

Bayer Target price 2025 - Analyst rating & recommendation

Bayer Classifications & Recommendation:

Buy
43%
Hold
54%
Sell
4%

Bayer Price Target

Target Price €28.56
Price €27.50
Potential 3.85%
Number of Estimates 24
24 Analysts have issued a price target Bayer 2026 . The average Bayer target price is €28.56. This is 3.85% higher than the current stock price. The highest price target is €36.75 33.64% , the lowest is €23.23 15.53% .
A rating was issued by 28 analysts: 12 Analysts recommend Bayer to buy, 15 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Bayer stock has an average upside potential 2026 of 3.85% . Most analysts recommend the Bayer stock at Hold.

Sales and Margin forecast 2025, 2026 to 2032


Dec '24 2025
Estimates
Revenue Billion € 46.61 46.71
2.16% 0.22%
EBITDA Margin 27.42% 20.31%
29.18% 25.93%
Net Margin -5.48% 9.93%
11.31% 281.35%

24 Analysts have issued a sales forecast Bayer 2025 . The average Bayer sales estimate is €46.7b . This is 1.16% higher than the revenue of the last 12 months(TTM). The highest sales forecast is €48.8b 5.78% , the lowest is €44.2b 4.31% .

This results in the following potential growth metrics:

Revenue Estimates

2024 €46.6b 2.16%
2025 €46.7b 0.22%
2026 €47.2b 1.01%
2027 €48.3b 2.29%
2028 €49.6b 2.76%
2029 €50.2b 1.13%
2030 €51.9b 3.43%
2031 €50.3b 3.09%
2032 €50.9b 1.32%

23 Analysts have issued an Bayer EBITDA forecast 2025. The average Bayer EBITDA estimate is €9.5b . This is 43.23% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is €11.6b 74.50% , the lowest is €7.9b 19.19% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 €12.8b 30.71%
2025 €9.5b 25.77%
2026 €9.9b 4.46%
2027 €10.3b 4.30%
2028 €9.8b 5.43%
2029 €9.7b 0.79%

EBITDA Margin

2024 27.42% 29.18%
2025 20.31% 25.93%
2026 21.00% 3.40%
2027 21.41% 1.95%
2028 19.71% 7.94%
2029 19.33% 1.93%

23 Bayer Analysts have issued a net profit forecast 2025. The average Bayer net profit estimate is €4.6b . This is 235.75% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is €5.3b 256.12% , the lowest is €4.1b 219.99% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 €-2.6b 13.23%
2025 €4.6b 281.82%
2026 €4.8b 3.66%
2027 €5.3b 9.66%
2028 €5.7b 8.10%
2029 €5.8b 1.12%
2030 €6.4b 10.92%

Net Margin

2024 -5.48% 11.31%
2025 9.93% 281.35%
2026 10.19% 2.62%
2027 10.93% 7.26%
2028 11.50% 5.22%
2029 11.50% 0.00%
2030 12.33% 7.22%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032


Dec '24 2025
Estimates
Earnings Per Share -2.60 4.72
13.04% 281.54%
P/E 5.82
EV/Sales 1.28

23 Analysts have issued a Bayer forecast for earnings per share. The average Bayer EPS is €4.72 . This is 235.63% higher than earnings per share in the financial year 2024. The highest EPS forecast is €5.43 256.03% , the lowest is €4.17 219.83% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 €-2.60 13.04%
2025 €4.72 281.54%
2026 €4.90 3.81%
2027 €5.37 9.59%
2028 €5.80 8.01%
2029 €5.87 1.21%
2030 €6.51 10.90%
2031 €4.70 27.80%
2032 €4.86 3.40%

P/E ratio

Current -7.90 62.22%
2025 5.82 173.65%
2026 5.62 3.44%
2027 5.12 8.90%
2028 4.74 7.42%
2029 4.69 1.05%
2030 4.22 10.02%

Based on analysts' sales estimates for 2025, the Bayer stock is valued at an EV/Sales of 1.28 and an P/S ratio of 0.58 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 1.30 2.99%
2025 1.28 1.19%
2026 1.27 1.00%
2027 1.24 2.24%
2028 1.21 2.69%
2029 1.20 1.12%
2030 1.16 3.31%
2031 1.19 3.19%
2032 1.18 1.31%

P/S ratio

Current 0.59 4.19%
2025 0.58 1.16%
2026 0.57 1.00%
2027 0.56 2.23%
2028 0.55 2.69%
2029 0.54 1.12%
2030 0.52 3.30%
2031 0.54 3.18%
2032 0.53 1.30%

Current Bayer Upgrades & Downgrades

Analyst Rating Action Date
BERENBERG
Hold
Hold
Unchanged Sep 11 2025
LANDESBANK BADEN-WUERTTEMBERG
Hold
Hold
Unchanged Aug 29 2025
HSBC GLOBAL INVESTMENT RESEARCH
Buy
Buy
Unchanged Aug 25 2025
JEFFERIES
Hold
Hold
Unchanged Aug 18 2025
SOLVENTIS RESEARCH
Buy
Buy
Unchanged Aug 13 2025
ROTHSCHILD & CO REDBURN
Neutral
Neutral
Unchanged Aug 13 2025
DZ BANK
Buy
Buy
Unchanged Aug 12 2025
Analyst Rating Date
Unchanged
BERENBERG:
Hold
Hold
Sep 11 2025
Unchanged
LANDESBANK BADEN-WUERTTEMBERG:
Hold
Hold
Aug 29 2025
Unchanged
HSBC GLOBAL INVESTMENT RESEARCH:
Buy
Buy
Aug 25 2025
Unchanged
JEFFERIES:
Hold
Hold
Aug 18 2025
Unchanged
SOLVENTIS RESEARCH:
Buy
Buy
Aug 13 2025
Unchanged
ROTHSCHILD & CO REDBURN:
Neutral
Neutral
Aug 13 2025
Unchanged
DZ BANK:
Buy
Buy
Aug 12 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today